Industry leaders at CPHI Frankfurt this week discussed embracing technologies such as automation, AI, and innovative manufacturing platforms all in an effort to improve efficiency, quality, scalability and sustainability in pharmaceutical production and development
As part of a three-part feature with Manufacturing Chemist, our Chief Strategy Officer, Matthew Paterson, shared: "As a CDMO partner, we are increasingly able to support clients that are looking for US-based drug product manufacturing support. The ongoing discussions and incentives to bring pharmaceutical manufacturing back onshore in the US has sparked more attention in services available from our Philadelphia-based facilities."
CDMO facilities in Philadelphia have been part of Quotient Sciences’ sites for nearly 10 years. These facilities feature drug product formulation and manufacturing capabilities for all stages of development, from clinical to commercial scale, and are part of executing integrated Translational Pharmaceutics programs for US-based clients.
"More companies are exploring their options from US-based providers, and we’re well-positioned to assist clients by offering services from both our UK and US locations." he says.
The article features Quotient Sciences contributions along with other industry experts, highlighting the challenges and solutions involved in process optimisation, technology transfer and the adoption of digital and sustainable manufacturing methods. Read the three-part series on the Manufacturing Chemist website:
Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)
Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part II)
Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)